These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 25622123)

  • 1. Impact of prospectively determined A118G polymorphism on treatment response to injectable naltrexone among methamphetamine-dependent patients: an open-label, pilot study.
    Pal R; Mendelson JE; Flower K; Garrison K; Yount G; Coyle JR; Galloway GP
    J Addict Med; 2015; 9(2):130-5. PubMed ID: 25622123
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utilizing a Two-stage Design to Investigate the Safety and Potential Efficacy of Monthly Naltrexone Plus Once-daily Bupropion as a Treatment for Methamphetamine Use Disorder.
    Mooney LJ; Hillhouse MP; Thomas C; Ang A; Sharma G; Terry G; Chang L; Walker R; Trivedi M; Croteau D; Sparenborg S; Ling W
    J Addict Med; 2016; 10(4):236-43. PubMed ID: 27379819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Effects of Naltrexone on Subjective Response to Methamphetamine in a Clinical Sample: a Double-Blind, Placebo-Controlled Laboratory Study.
    Ray LA; Bujarski S; Courtney KE; Moallem NR; Lunny K; Roche D; Leventhal AM; Shoptaw S; Heinzerling K; London ED; Miotto K
    Neuropsychopharmacology; 2015 Sep; 40(10):2347-56. PubMed ID: 25801501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bupropion and Naltrexone in Methamphetamine Use Disorder.
    Trivedi MH; Walker R; Ling W; Dela Cruz A; Sharma G; Carmody T; Ghitza UE; Wahle A; Kim M; Shores-Wilson K; Sparenborg S; Coffin P; Schmitz J; Wiest K; Bart G; Sonne SC; Wakhlu S; Rush AJ; Nunes EV; Shoptaw S
    N Engl J Med; 2021 Jan; 384(2):140-153. PubMed ID: 33497547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of the OPRM1 A118G polymorphism on alcohol-induced euphoria, risk for alcoholism and the clinical efficacy of naltrexone.
    Setiawan E; Pihl RO; Benkelfat C; Leyton M
    Pharmacogenomics; 2012 Jul; 13(10):1161-72. PubMed ID: 22909206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extended-Release Naltrexone to Prevent Opioid Relapse in Criminal Justice Offenders.
    Lee JD; Friedmann PD; Kinlock TW; Nunes EV; Boney TY; Hoskinson RA; Wilson D; McDonald R; Rotrosen J; Gourevitch MN; Gordon M; Fishman M; Chen DT; Bonnie RJ; Cornish JW; Murphy SM; O'Brien CP
    N Engl J Med; 2016 Mar; 374(13):1232-42. PubMed ID: 27028913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extended-release naltrexone for methamphetamine dependence among men who have sex with men: a randomized placebo-controlled trial.
    Coffin PO; Santos GM; Hern J; Vittinghoff E; Santos D; Matheson T; Colfax G; Batki SL
    Addiction; 2018 Feb; 113(2):268-278. PubMed ID: 28734107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interacting effects of naltrexone and OPRM1 and DAT1 variation on the neural response to alcohol cues.
    Schacht JP; Anton RF; Voronin KE; Randall PK; Li X; Henderson S; Myrick H
    Neuropsychopharmacology; 2013 Feb; 38(3):414-22. PubMed ID: 23032071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An open clinical trial of naltrexone for amphetamine dependence: compliance and tolerability.
    Jayaram-Lindström N; Wennberg P; Beck O; Franck J
    Nord J Psychiatry; 2005; 59(3):167-71. PubMed ID: 16195116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Opioid treatment at release from jail using extended-release naltrexone: a pilot proof-of-concept randomized effectiveness trial.
    Lee JD; McDonald R; Grossman E; McNeely J; Laska E; Rotrosen J; Gourevitch MN
    Addiction; 2015 Jun; 110(6):1008-14. PubMed ID: 25703440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. OPRM1 A118G genotype fails to predict the effectiveness of naltrexone treatment for alcohol dependence.
    Coller JK; Cahill S; Edmonds C; Farquharson AL; Longo M; Minniti R; Sullivan T; Somogyi AA; White JM
    Pharmacogenet Genomics; 2011 Dec; 21(12):902-5. PubMed ID: 21946895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: a double-blind placebo-controlled study.
    Ray LA; Hutchison KE
    Arch Gen Psychiatry; 2007 Sep; 64(9):1069-77. PubMed ID: 17768272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Opioid Antagonists and the A118G Polymorphism in the μ-Opioid Receptor Gene: Effects of GSK1521498 and Naltrexone in Healthy Drinkers Stratified by OPRM1 Genotype.
    Ziauddeen H; Nestor LJ; Subramaniam N; Dodds C; Nathan PJ; Miller SR; Sarai BK; Maltby K; Fernando D; Warren L; Hosking LK; Waterworth D; Korzeniowska A; Win B; Richards DB; Vasist Johnson L; Fletcher PC; Bullmore ET
    Neuropsychopharmacology; 2016 Oct; 41(11):2647-57. PubMed ID: 27109624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of µ-opioid receptor (OPRM1) gene polymorphism with response to naltrexone in alcohol dependence: a systematic review and meta-analysis.
    Chamorro AJ; Marcos M; Mirón-Canelo JA; Pastor I; González-Sarmiento R; Laso FJ
    Addict Biol; 2012 May; 17(3):505-12. PubMed ID: 22515274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A preliminary randomized clinical trial of naltrexone reduces striatal resting state functional connectivity in people with methamphetamine use disorder.
    Kohno M; Dennis LE; McCready H; Schwartz DL; Hoffman WF; Korthuis PT
    Drug Alcohol Depend; 2018 Nov; 192():186-192. PubMed ID: 30266003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The μ-opioid receptor and treatment response to naltrexone.
    Thorsell A
    Alcohol Alcohol; 2013; 48(4):402-8. PubMed ID: 23543091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Separate and Combined Effects of Naltrexone and Extended-Release Alprazolam on the Reinforcing, Subject-Rated, and Cardiovascular Effects of Methamphetamine.
    Marks KR; Lile JA; Stoops WW; Glaser PE; Hays LR; Rush CR
    J Clin Psychopharmacol; 2016 Jun; 36(3):213-21. PubMed ID: 27043121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A micro opioid receptor gene polymorphism (A118G) and naltrexone treatment response in adherent Korean alcohol-dependent patients.
    Kim SG; Kim CM; Choi SW; Jae YM; Lee HG; Son BK; Kim JG; Choi YS; Kim HO; Kim SY; Oslin DW
    Psychopharmacology (Berl); 2009 Jan; 201(4):611-8. PubMed ID: 18795264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Randomised, Double-Blind, Placebo-Controlled Trial of As-Needed Naltrexone in the Treatment of Pathological Gambling.
    Kovanen L; Basnet S; Castrén S; Pankakoski M; Saarikoski ST; Partonen T; Alho H; Lahti T
    Eur Addict Res; 2016; 22(2):70-9. PubMed ID: 26339899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Naltrexone for the treatment of amphetamine dependence: a randomized, placebo-controlled trial.
    Jayaram-Lindström N; Hammarberg A; Beck O; Franck J
    Am J Psychiatry; 2008 Nov; 165(11):1442-8. PubMed ID: 18765480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.